Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Other Operating Expenses (2016 - 2025)

Protalix BioTherapeutics has reported Other Operating Expenses over the past 11 years, most recently at -$6.9 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$6.9 million for Q4 2025, down 24.45% from a year ago — trailing twelve months through Dec 2025 was -$11.2 million (down 239.92% YoY), and the annual figure for FY2025 was -$11.7 million, down 34.19%.
  • Other Operating Expenses for Q4 2025 was -$6.9 million at Protalix BioTherapeutics, down from $22000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for PLX hit a ceiling of $1.4 million in Q3 2024 and a floor of -$6.9 million in Q4 2025.